Literature DB >> 4051313

Maximal inspiratory and expiratory pressures are reduced in hyperinflated, malnourished, young adult male patients with cystic fibrosis.

A Szeinberg, S England, C Mindorff, I M Fraser, H Levison.   

Abstract

We measured maximal inspiratory and expiratory pressures (MIP and MEP, respectively) in 23 male patients with cystic fibrosis (CF), 16 to 35 yr of age (22.1 +/- 3.7), and in a control group of 33 male volunteers, 17 to 39 yr of age (22.5 +/- 6.8), to evaluate the effects of chronic hyperinflation and malnutrition on MIP and MEP in the patients with CF. Routine pulmonary function tests and skeletal muscle indexes, such as the force generated by the adductor pollicis muscle with supramaximal ulnar nerve stimulation at a frequency of 10 Hz as percentage of force at 100 Hz (F10/100) and midarm muscle circumference as a percentage of predicted (MAMC), were also measured in the patients with CF. Severe hyperinflation in this study was defined as a ratio of residual volume to total lung capacity above 50% and malnutrition as a ratio of actual weight to the ideal weight for the patient's age and height of 90% or less. The severely hyperinflated subgroup of patients with CF had significantly reduced MIP values in comparison with those in the other patients with CF. The malnourished subgroup, which was also severely hyperinflated, differed from the well-nourished one in both skeletal muscle indexes; MAMC was reduced, whereas F10/100 was elevated, and respiratory muscle pressure generation, MIP, and MEP were reduced. We conclude that patients with CF who are malnourished and/or severely hyperinflated have reduced maximal respiratory pressures.

Entities:  

Mesh:

Year:  1985        PMID: 4051313     DOI: 10.1164/arrd.1985.132.4.766

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis.

Authors:  A E Holland; L Denehy; G Ntoumenopoulos; M T Naughton; J W Wilson
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

2.  Respiratory muscle function in cystic fibrosis.

Authors:  A Mier; A Redington; C Brophy; M Hodson; M Green
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

Review 3.  Urinary incontinence in cystic fibrosis.

Authors:  Mary E Dodd; Hannah Langman
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

4.  Prevalence of Fecal Incontinence in Adults with Cystic Fibrosis.

Authors:  Alban Benezech; Nadine Desmazes-Dufeu; Karine Baumstarck; Michel Bouvier; Bérengère Coltey; Martine Reynaud-Gaubert; Véronique Vitton
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

Review 5.  Exercise recommendations for individuals with cystic fibrosis.

Authors:  S R Boas
Journal:  Sports Med       Date:  1997-07       Impact factor: 11.136

Review 6.  Exercise response and rehabilitation in cystic fibrosis.

Authors:  G J Canny; H Levison
Journal:  Sports Med       Date:  1987 Mar-Apr       Impact factor: 11.136

7.  How Many Maneuvers Should We Do for Maximal Inspiratory and Expiratory Muscle Pressure Testing in Children: A Retrospective Review in Children with Cystic Fibrosis.

Authors:  Wicharn Boonjindasup; Anne B Chang; Julie M Marchant; J Yoon Irons; Margaret S McElrea
Journal:  Lung       Date:  2021-02-15       Impact factor: 2.584

Review 8.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis.

Authors:  Richard Kraemer; David N Baldwin; Roland A Ammann; Urs Frey; Sabina Gallati
Journal:  Respir Res       Date:  2006-11-30

Review 10.  A practical approach to oxygen therapy in cystic fibrosis.

Authors:  M E Dodd; C S Haworth; A K Webb
Journal:  J R Soc Med       Date:  1998       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.